Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Category list : Safety warnings

Sort by: Newest first Oldest first A-Z Z-A

  • Zoledronic acid 'patient card' would reduce risk of bone tissue death Subscription

    16 MAR 2015 14:35

    Use of a patient reminder card has been recommended by a committee of the European Medicines Agency to minimise the risk of jaw osteonecrosis associated with zoledronic acid.

  • Xgeva warning Subscription

    7 AUG 2015 9:43

    The summary of product characteristics (SPC) for Xgeva (denosumab; Amgen) now warns that the start of treatment or new treatment course should be delayed in patients with unhealed open soft tissue lesions in the mouth. In addition, poorly fitting dentures are now a risk factor to consider before starting treatment and invasive dental procedures should be avoided during treatment. This is because of the risk of osteonecrosis of the jaw. Detailed information can be found in the SPC

  • Methotrexate

    Unsafe methotrexate prescribing remains common in England, study finds Subscription

    23 JUN 2020 15:23 By Julia Robinson

    Unsafe methotrexate prescribing has gradually reduced but is still common, with substantial variation between general practices in England, a study in the British Journal of General Practice has found.

  • Timeline and infographic showing the development and safety of proton pump inhibitors

    The development and safety of proton pump inhibitors Subscription

    24 JUN 2016 12:03 By Dawn Connelly

    Since the discovery of omeprazole in 1979, dispensing of proton pump inhibitors (PPIs) in England has increased more than 100-fold, and several products are now available without prescription. Although PPIs are effective and generally well tolerated, observational studies suggest an association with several adverse effects. Further trials are needed to establish causal relationships. 

  • Woman unable to sleep

    Strengthened drowsiness warnings proposed for zolpidem-containing medicines

    10 MAR 2014 18:41

    Strengthened warnings about the risk of next-day drowsiness after taking zolpidem are set to be included in revised product information, following a safety review by the European Medicines Agency.

  • SSRIs still prescribed for children, despite safety warnings

    24 DEC 2005 0:00

    Selective serotonin reuptake inhibitors continue to be prescribed for the management of childhood depression, despite warnings from regulatory authorities, a review of prescribing practices in Ireland has revealed.

  • Simponi adverse events Subscription

    18 JAN 2016 15:53

    The summary of product characteristics for Simponi (golimumab) solution for injection, used to treat a variety of rheumatic diseases, has been updated to add extra warnings to highlight that there have been cases of fatal congestive heart failure, invasive fungal infections and leukaemia in patients.

  • Ash Soni, president of the Royal Pharmaceutical Society

    RPS urges home secretary to ban DNP 'diet' drug

    1 APR 2019 11:17

    The Royal Pharmaceutical Society has written to Sajid Javid, the home secretary, requesting an immediate ban on the diet drug 2,4-dinitrophenol.

  • A patient information card that pharmacists can give to female patients to warn them about the risks of taking valproate while pregnant has been produced by the MHRA. In the image, a group of pregnant women

    Resources launched to help female patients understand risks of valproate treatment Subscription

    10 FEB 2016 15:43
    Comments (1)

    A credit card-sized patient information card that pharmacists can give to female patients to warn them about the risks of taking valproate while pregnant has been produced by the Medicines and Healthcare products Regulatory Agency.

  • Recall of Ebixa Subscription

    19 DEC 2014 15:29

    The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 2 medicines recall for specific batches of Ebixa (memantine hydrochloride; Lundbeck) 5mg/pump actuation 50ml and 100ml bottle. This is because of a fault with some of the pump devices which may result in suboptimal dosage of the product. Further information is available on the MHRA website.

Show  10 per page20 per page50 per page

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.